05B · Claim Check
Xanamem · Actinogen XanaMIA · NCT06125951
- Readout
- Xanamem · Actinogen XanaMIA · NCT06125951 (opens another website in a new tab)
- What the registry or primary source says
- Phase 2/3. Primaries: CDR-SB change at 36 weeks; adverse events. N=247; active, not recruiting; primary completion 09.22.2026.
- What the headline says
- Primary missed: 0.10 points vs placebo, p = 0.65
- Verdict
- Match
Bookmarks need a Mind Club sign-in. How sign-in works
Read it in Claim Check